Titration window
About 16 weeks to reach injectable maintenance dose per FDA labeling.
Protocol / Research Dosing Guide
Semaglutide Dosage Guide: FDA Titration Schedules, Reconstitution and Safety
An evidence-organized Semaglutide reference that reports the FDA-approved Ozempic, Wegovy and Rybelsus titration schedules alongside the reconstitution math used for research-labeled vials.
Last reviewed September 16, 202617 minute readResearch information only
Level 6 — Multiple FDA-approved productsInjectable and oral titrations differ by indicationResearch-labeled vials are not the approved product
Semaglutide Quick Start
Semaglutide is a GLP-1 receptor agonist sold under three FDA-approved brand names that share one active molecule. The injectable and oral forms are titrated on different schedules and cap at different maintenance doses depending on indication. Research-labeled vials sold outside a pharmacy are not the approved drug product and carry no independent approval or quality assurance.
Why researchers care
Glycemic control and chronic weight management
Class
GLP-1 receptor agonist, 31-amino-acid peptide analogue of human GLP-1
Route reported
Subcutaneous injection once weekly (Ozempic, Wegovy); oral tablet once daily (Rybelsus, Wegovy oral)
Cycle length
About 16 weeks of titration to the injectable maintenance dose, then ongoing weekly maintenance
Regulatory status
FDA approved as Ozempic (type 2 diabetes), Wegovy injection and Wegovy oral tablet (chronic weight management), and Rybelsus (type 2 diabetes); research-labeled vials are not an approved product
Loading supplier information
Semaglutide Dosing Protocol and Schedule
The supplied source reports the FDA-labeled Wegovy injectable titration to a 2.4 mg weekly maintenance dose over about 16 weeks, the Ozempic type 2 diabetes titration capping at 2.0 mg weekly, the Rybelsus oral titration to a 14 mg daily maximum, and the Wegovy 25 mg oral tablet titration approved in December 2025.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Injectable weeks 1–4 | 0.25 mg once weekly | FDA labeling |
| Injectable weeks 5–8 | 0.5 mg once weekly | FDA labeling |
| Injectable weeks 9–12 | 1.0 mg once weekly | FDA labeling |
| Injectable weeks 13–16 | 1.7 mg once weekly | FDA labeling |
| Injectable week 17+ | 2.4 mg once weekly (Wegovy) or 2.0 mg once weekly maximum (Ozempic) | FDA labeling |
| Rybelsus oral | 3 mg, then 7 mg, then 14 mg once daily | FDA labeling |
| Wegovy oral tablet | 1.5 mg, then 4 mg, then 9 mg, then 25 mg once daily | FDA labeling |
Injectable and oral forms are not dose-equivalent and are not interchangeable. FDA labeling permits extending any titration step by 4 additional weeks for tolerability and temporarily stepping down one level if the top dose is not tolerated.
Semaglutide Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Bacteriostatic water at a measured volume
Research planning item
U-100 insulin syringes
Research planning item
Alcohol prep swabs
Research planning item
Sharps container
Research planning item
Refrigeration for the prepared vial
Research planning item
Written concentration label with the preparation date
Semaglutide Reconstitution Calculator
Vial-format concentration math
Concentration
5 mg/mL
Draw volume
0.05 mL
U-100 units
5
Mathematical draws
40
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take Semaglutide: Morning or Night?
Morning or evening?
Not established for injection; any consistent day of the week is the FDA-labeled pattern. Oral tablets are taken first thing in the morning.
Once weekly or daily?
Injectable Ozempic and Wegovy are once weekly. Rybelsus and the Wegovy tablet are once daily.
With food?
Oral tablets must be taken on an empty stomach with up to 4 oz of plain water, waiting 30 minutes before food, drink, or other oral medicine.
Missed amount?
FDA labeling for the injectable states a missed weekly dose may be taken within 5 days; beyond that, skip it and resume the regular schedule.
Semaglutide Route Comparison
| Format | What is reported | Evidence limit |
|---|---|---|
| Subcutaneous injection | Once weekly, abdomen, thigh, or upper arm | FDA-approved route for Ozempic and Wegovy |
| Oral tablet | Once daily, empty stomach | FDA-approved route for Rybelsus and Wegovy oral; bioavailability is low (about 1%) and dose is not equivalent to injection |
| Research-labeled vial | Sold for reconstitution and subcutaneous injection | Not an FDA-approved product; sterility, potency and content are not independently verified |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
Semaglutide Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Human plasma half-life | About 7 days | Supports once-weekly injectable dosing |
| Time to steady state | Roughly 4–5 weeks at a given dose | Consistent with the 4-week titration steps |
| Oral bioavailability | About 1% | Explains the strict empty-stomach administration requirement |
| Frequency logic | Weekly injection and daily tablet dosing both reflect FDA-approved labeling | Established |
Semaglutide Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous | 0.25 mg | Once weekly, weeks 1–4 | FDA labeling | Tolerability step, not therapeutic |
| Subcutaneous | 1.0 mg | Once weekly | FDA labeling | Ozempic type 2 diabetes range |
| Subcutaneous | 2.4 mg | Once weekly maintenance | FDA labeling | Wegovy weight-management maintenance |
| Oral | 14 mg | Once daily maximum | FDA labeling | Rybelsus maximum |
| Oral | 25 mg | Once daily maintenance | FDA labeling | Wegovy oral tablet maintenance |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
Semaglutide Reconstitution Guide
Concentration: 5 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 0.25 mg | 0.05 mL | 5 units |
| 0.5 mg | 0.1 mL | 10 units |
| 0.75 mg | 0.15 mL | 15 units |
- 1.Confirm the exact quantity printed on the vial label.
- 2.Choose and record the measured bacteriostatic water volume.
- 3.Clean the vial stopper with an alcohol swab.
- 4.Add the liquid slowly down the vial wall.
- 5.Swirl gently until clear; never shake.
- 6.Inspect for cloudiness, discoloration, or particles and discard anything that is not clear.
- 7.Label the vial with the calculated concentration and preparation date.
- 8.Use only the calculated concentration for syringe unit arithmetic.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How Semaglutide Works
Receptor target
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1.
Semaglutide Human Trials and FDA Status
Current status · verified September 16, 2026
FDA approved as Ozempic (type 2 diabetes), Wegovy injection and Wegovy oral tablet (chronic weight management), and Rybelsus (type 2 diabetes); research-labeled vials are not an approved product
- The STEP 1 trial reported a 14.9% mean weight loss at 68 weeks with 2.4 mg weekly Wegovy versus placebo, in adults with obesity or overweight and a weight-related condition.
- SUSTAIN program trials established the glycemic efficacy and safety basis for Ozempic in type 2 diabetes across a range of weekly doses up to 2.0 mg.
- The PIONEER program established the safety and efficacy of oral Rybelsus in type 2 diabetes at daily doses up to 14 mg.
- The OASIS program, including OASIS 4, supported approval of the Wegovy 25 mg oral tablet, reporting 16.6% weight loss at 64 weeks.
Who Should Avoid Semaglutide?
This is an evidence-gap and precaution list, not an approved prescribing label.
Personal or family history of medullary thyroid carcinoma or MEN 2
Boxed warning in FDA labeling
Pregnancy
Not recommended; discontinue before a planned pregnancy per labeling
History of pancreatitis
Labeling advises caution and monitoring
Severe gastrointestinal disease
Delayed gastric emptying can worsen these conditions
Diabetic retinopathy under treatment
Labeling flags a risk of complication during rapid glycemic improvement
Unverified research-labeled vials
No independent verification of content or sterility
Semaglutide Side Effects, Risks and Safety
Nausea, vomiting, diarrhea, constipationVery common in trials
Important limitation: Most frequent during dose escalation.
Injection-site reactionsCommon
Important limitation: Reported in labeling for the injectable form.
Gallbladder diseaseReported in trials
Important limitation: Rapid weight loss is a contributing factor.
PancreatitisUncommon but labeled
Important limitation: Requires prompt evaluation of persistent abdominal pain.
Thyroid C-cell tumorsBoxed warning based on rodent findings
Important limitation: Human relevance not established.
Diabetic retinopathy complicationsReported in a cardiovascular outcomes trial population
Important limitation: Monitor in those with existing retinopathy.
Semaglutide Timeline and Monitoring
Side-effect pattern
Gastrointestinal effects are most common during escalation and typically ease by around week 20 per trial reporting.
Weight-loss trajectory
Continued loss is reported through 68 weeks in the pivotal weight-management trial.
Monitoring
Periodic review of tolerability, and for diabetes indications, glycemic markers, per labeling.
Semaglutide Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Glycemic control in type 2 diabetes | Established | Multiple randomized SUSTAIN and PIONEER trials | FDA-approved indication |
| Chronic weight management | Established | STEP and OASIS randomized trial programs | FDA-approved indication |
| Cardiovascular risk reduction | Established in a specific trial population | SELECT and related outcomes data | Indication-specific; not a general claim |
| Off-label or unapproved uses | Not established | Not within FDA-approved labeling | Outside the reviewed evidence |
Semaglutide Storage and Handling
Unopened FDA-approved pen or vial
Refrigerated per manufacturer labeling; some products allow room-temperature storage for a limited time.
Research-labeled lyophilized vial
Refrigerated or frozen per the supplier label; no independent stability study was identified.
Prepared vial
Refrigerate and use within the timeframe stated on the product labeling; discard if cloudy or discolored.
Appearance
Clear and colorless is expected; particles or discoloration mean discard.
Semaglutide Troubleshooting
Persistent nausea after a dose increase
Labeling permits extending the current step by 4 weeks before advancing further.
Top dose not tolerated
Labeling allows a temporary step-down to the prior dose.
Missed weekly injection
Labeling allows dosing within 5 days of the missed date; otherwise skip and resume the regular schedule.
Oral tablet taken with food by mistake
Absorption is likely reduced for that dose; resume normal empty-stomach dosing at the next scheduled tablet.
Calculated syringe units look wrong
Recheck vial quantity, diluent volume, and target dose arithmetic.
Semaglutide Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Multiple FDA-approved products | Once weekly (injectable) or once daily (oral) |
| Tirzepatide | Dual GIP/GLP-1 receptor agonist | FDA approved (Mounjaro, Zepbound) | Once weekly |
| Liraglutide | GLP-1 receptor agonist | FDA approved (Saxenda, Victoza) | Once daily |
| Research-labeled semaglutide vial | Same molecule, unapproved product | No independent approval | Varies by supplier |
Semaglutide Frequently Asked Questions
What is semaglutide?
A GLP-1 receptor agonist peptide sold as Ozempic, Wegovy, and Rybelsus, all made by Novo Nordisk.
Is semaglutide FDA approved?
Yes, as Ozempic and Wegovy (injectable), Wegovy oral tablet, and Rybelsus, each with its own approved indication and dosing cap.
What is the maintenance dose for weight management?
2.4 mg once weekly for injectable Wegovy, or 25 mg once daily for the Wegovy oral tablet, per FDA labeling.
What is the maximum dose for type 2 diabetes?
2.0 mg once weekly for injectable Ozempic, or 14 mg once daily for Rybelsus.
How long does titration take?
About 16 weeks to reach the injectable maintenance dose under standard FDA-labeled escalation.
What is its half-life?
About 7 days, which supports once-weekly injection.
Can a missed dose be made up?
FDA labeling allows dosing within 5 days for the injectable form; beyond that, skip and resume the regular schedule.
Are research-labeled vials the same as the approved drug?
No. They are not FDA approved and are not independently verified for content or sterility.
What are the most common side effects?
Nausea, vomiting, diarrhea, and constipation, most common during dose escalation.
Is there a boxed warning?
Yes, regarding thyroid C-cell tumors seen in rodent studies; human relevance is not established.
Can oral and injectable doses be swapped directly?
No. The two routes use different titration schedules and are not dose-equivalent.
Sources and Research
Coverage source
1. Semaglutide protocol coverage source
Titration schedules, reconstitution math, and page structure; not primary evidence.
Open direct sourceFDA labeling
2. Ozempic (semaglutide) injection FDA prescribing information
FDA-approved labeling for type 2 diabetes dosing and safety.
Open direct sourceFDA labeling
3. Wegovy (semaglutide) injection FDA prescribing information
FDA-approved labeling for chronic weight management dosing and safety.
Open direct sourceHuman research
4. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Randomized trial reporting 14.9% mean weight loss at 68 weeks.
Open direct sourceFDA labeling
5. Rybelsus (oral semaglutide) FDA prescribing information
FDA-approved labeling for the oral tablet in type 2 diabetes.
Open direct sourceMissing information flagged for review
- Independent verification of research-labeled vial content and sterility: Not established
- Long-term outcomes beyond published trial durations: Not established
- Head-to-head oral-versus-injectable dose equivalence: Not established
- Use in populations excluded from pivotal trials: Not established